Cipla receives final approval for generic version of Shire's Firazyr®

Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla's Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire's Firazyr®. Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. According to IQVIA (IMS Health), Firazyr® and its generic equivalents had US sales of approximately $270M for the 12-month period ending May 2020.

Shares of CIPLA LTD. was last trading in BSE at Rs.638.15 as compared to the previous close of Rs. 638.65. The total number of shares traded during the day was 97002 in over 2051 trades.

The stock hit an intraday high of Rs. 645.9 and intraday low of 636.75. The net turnover during the day was Rs. 62175194.

Source : Equity Bulls

Keywords